09.01.05
Herbal ingredient supplier, Linnea SA, Locarno, Switzerland, recently unveiled its first branded ingredient, HMRlignan, to the supplement market. Derived from Norway Spuce (picea abies), this patented product, which was developed by Finland-based Hormos Medical Corporation, has been licensed by Linnea and will be marketed and manufactured worldwide by the company. According to Robin Ward, commercial manager for Linnea, the supplement market will be HMRlignan’s first stop for introduction, with the food and beverage industry to follow in the future. NDI clearance from FDA was achieved in May, and generally recognized and safe (GRAS) and novel food applications are currently being prepared.
HMRlignan is the result of several years of research to achieve an efficient dose response in lignan pharmacology to encourage the body’s natural production of enterolactone as a direct precursor. Enterolactone is the human metabolite of plant lignans usually present in low concentrations in the human diet. Research indicates that low plasma enterolactone levels are correlated with increased risks of the development of cardiovascular disease and hormonally related cancers, especially breast and prostate cancers. HMRlignan also possesses significant antioxidant capacity, comparable to that of vitamin E, which adds to its protective effect in the body. Looking to capitalize on the steady growth and interest in lignans, Linnea is offering HMRlignan as an ingredient that will give formulators significant advantages in price, dosage and bioavailability. It is also has an advantage in that it does not cause some of the gastrointestinal side effects sometimes associated with other lignan-based products on the market.
HMRlignan is the result of several years of research to achieve an efficient dose response in lignan pharmacology to encourage the body’s natural production of enterolactone as a direct precursor. Enterolactone is the human metabolite of plant lignans usually present in low concentrations in the human diet. Research indicates that low plasma enterolactone levels are correlated with increased risks of the development of cardiovascular disease and hormonally related cancers, especially breast and prostate cancers. HMRlignan also possesses significant antioxidant capacity, comparable to that of vitamin E, which adds to its protective effect in the body. Looking to capitalize on the steady growth and interest in lignans, Linnea is offering HMRlignan as an ingredient that will give formulators significant advantages in price, dosage and bioavailability. It is also has an advantage in that it does not cause some of the gastrointestinal side effects sometimes associated with other lignan-based products on the market.